id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-030361-0tepkjdl	Mohammed Abdul, Mubeen Khan	Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure	2020-08-11		.txt	text/plain	4991	233	42	In a study conducted by Foster and colleagues, data was combined from nine phase 2 and phase 3 clinical trials to evaluate efficacy and safety outcomes in HCV patients ≥ 65 years old treated with the pan-genotypic regimen, glecaprevir/pibrentasvir, for 8, 12, or 16 weeks [28] . Shiffman and colleagues reported outcomes of 123 patients aged 65 years or older enrolled in three phase 3 studies who received sofosbuvir/velpatasvir, a pan-genotypic DAA, for 12 weeks for the treatment of chronic HCV [29] . Safety and efficacy of sofosbuvir/ velpatasvir for the treatment of chronic hepatitis C in patients aged 65 years or older: a retrospective analysis of phase 3 studies The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection	./cache/cord-030361-0tepkjdl.txt	./txt/cord-030361-0tepkjdl.txt